Received Oct 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | SC |
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | XX9N4 | SC / LA |
Measles-like rash; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of measles-like rash in a 32-year-old female patient who received MMR (Priorix) (batch number XX9N4, expiry date 01-JUN-2026) for prophylaxis. On 12-SEP-2025, the patient received the 1st dose of Priorix (subcutaneous, left arm) .5 ml. In SEP-2025, less than a week after receiving Priorix, the patient experienced measles-like rash (Verbatim: Measles-like rash). The outcome of the measles-like rash was unknown. It was unknown if the reporter considered the measles-like rash to be related to Priorix and Priorix Pre-Filled Syringe Device. It was unknown if the company considered the measles-like rash to be related to Priorix and Priorix Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 19-SEP-2025 A healthcare provider reported that she received the 1st dose of Priorix vaccine via subcutaneous route in the left arm on 12th September 2025. She further reported that she might had measle-like rash. No additional information or medical condition was reported.